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Abstract
Introduction:  Epistaxis  and  hypertension  are  frequent  conditions  in  the  adult  population.
Masked hypertension  is  deﬁned  as  a  clinical  condition  in  which  a  patient’s  ofﬁce  blood  pressure
level is  <140/90  mmHg,  but  the  ambulatory  or  home  blood  pressure  readings  are  in  the  hyper-
tensive range.  Many  studies  have  proved  that  hypertension  is  one  of  the  most  important  causes
of epistaxis.  The  prevalence  of  this  condition  in  patients  with  epistaxis  is  not  well  deﬁned.
Objective:  This  study  aimed  to  evaluate  the  prevalence  of  masked  hypertension  using  the
results of  ofﬁce  blood  pressure  measurement  compared  with  the  results  of  ambulatory  blood
pressure monitoring.
Methods:  Sixty  patients  with  epistaxis  and  60  control  subjects  were  enrolled  in  the  study.  All
patients with  epistaxis  and  controls  without  history  of  hypertension  underwent  physical  exami-
nation, including  ofﬁce  blood  pressure  measurement,  ambulatory  or  home  blood  pressure,  and
measurement  of  anthropometric  parameters.
Results:  Mean  age  was  similar  between  the  epistaxis  group  and  the  controls  --  21--68  years  (mean
42.9) for  the  epistaxis  group  and  18--71  years  (mean  42.2)  for  the  control  group.  A  total  of  20
patients (33.3%)  in  the  epistaxis  group  and  7  patients  (11.7%)  in  the  control  group  (p  =  0.004)
had masked  hypertension.  Night-time  systolic  blood  pressure  was  signiﬁcantly  higher  in  patients
with epistaxis  than  in  the  control  group  (p  <  0.005).  However,  no  signiﬁcant  difference  was  found
in daytime  systolic  blood  pressure  between  the  control  group  and  the  patients  with  epistaxis
(p =  0.517). Please cite this article as: Acar B, Yavuz B, Yıldız E, Ozkan S, Ayturk M, Sen O, et al. A possible cause of epistaxis: increased masked
hypertension prevalence in patients with epistaxis. Braz J Otorhinolaryngol. 2016. http://dx.doi.org/10.1016/j.bjorl.2016.01.007
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Conclusion:  This  study  demonstrates  increased  masked  hypertension  prevalence  in  patients
with epistaxis.  We  suggest  that  all  patients  with  epistaxis  should  undergo  ambulatory  or  home
blood pressure  to  detect  masked  hypertension,  which  could  be  a  possible  cause  of  epistaxis.
© 2016  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Published
by Elsevier  Editora  Ltda.  This  is  an  open  access  article  under  the  CC  BY  license  (http://
creativecommons.org/licenses/by/4.0/).
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Uma  possível  causa  de  epistaxe:  maior  prevalência  de  hipertensão  mascarada  em
pacientes  com  epistaxe
Resumo
Introduc¸ão:  Epistaxe  e  hipertensão  são  condic¸ões  frequentes  na  populac¸ão  adulta.  Hipertensão
mascarada  é  deﬁnida  como  uma  condic¸ão  clínica  em  que  o  nível  da  pressão  arterial  do  paciente
no consultório  é  <  140/90  mm  Hg,  mas  as  leituras  da  pressão  arterial  ambulatorial  ou  em  casa,
se encontram  na  faixa  hipertensiva.  Muitos  estudos  demonstraram  que  a  hipertensão  é  uma  das
causas mais  importantes  de  epistaxe.  Ainda  não  está  devidamente  deﬁnida  a  prevalência  dessa
condic¸ão em  pacientes  com  epistaxe.
Objetivo:  Esse  estudo  teve  por  objetivo  avaliar  a  prevalência  de  HM  com  o  uso  dos  resultados
de mensurac¸ões  da  pressão  arterial  no  consultório,  em  comparac¸ão  com  os  resultados  da  MAPA.
Método: Para  o  estudo,  foram  recrutados  60  pacientes  com  epistaxe  e  60  indivíduos  para  cont-
role. Todos  os  pacientes  com  epistaxe  e  os  controles  sem  histórico  de  hipertensão  passaram  por
exame físico,  inclusive  determinac¸ão  da  pressão  arterial  no  consultório,  MAPA  e  mensurac¸ão
dos parâmetros  antropométricos.
Resultados:  A  média  de  idade  foi  similar  entre  o  grupo  com  epistaxe  e  os  controles:  de  21
a 68  (média  42,9)  anos  para  o  grupo  com  epistaxe,  e  de  18  a  71  (média  42,2)  anos  para  o
grupo controle.  No  total,  20  pacientes  (33,3%)  no  grupo  com  epistaxe  e  7  pacientes  (11,7%)  no
grupo controle  (p  =  0,004)  apresentaram  hipertensão  mascarada.  A  pressão  arterial  sistólica
noturna foi  signiﬁcantemente  mais  alta  em  pacientes  com  epistaxe,  em  comparac¸ão  com  o
grupo controle  (p  <  0,005).  No  entanto,  não  foi  observada  diferenc¸a signiﬁcante  na  pressão
arterial sistólica  obtida  durante  o  dia  entre  o  grupo  controle  e  os  pacientes  com  epistaxe  (p  =
0,517).
Conclusão:  O  presente  estudo  demonstra  maior  prevalência  de  hipertensão  mascarada  em
pacientes com  epistaxe.  Sugerimos  que  todos  os  pacientes  com  epistaxe  devam  ser  submeti-
dos à  monitorac¸ão  da  pressão  arterial  caseira  ou  em  consultório  com  o  objetivo  de  detectar
hipertensão  mascarada,  que  pode  ser  uma  causa  possível  de  epistaxe.
© 2016  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Publicado
por Elsevier  Editora  Ltda.  Este e´  um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY  (http://
creativecommons.org/licenses/by/4.0/).
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leeding  in  the  nasal  cavity  caused  by  mucosa  injury  or
ascular  pathology  as  a  result  of  coagulation  disorders  is
nown  as  epistaxis.1 Epistaxis  is  one  of  the  most  common
ar--nose--throat  (ENT)  emergencies  that  require  hospital
dmission,  but  is  rarely  life  threatening.  Epistaxis  is  more
ommon  in  men  than  in  women,  and  its  frequency  increases
ith  age.1,2 The  incidence  of  epistaxis  is  not  exactly  known,
ut  it  is  approximately  7--60%  of  the  population.  Epis-
axis  can  be  post-traumatic,  iatrogenic  (nasal  surgery  or
ndoscopic  procedures),  and  spontaneous,  resulting  from
ossible  causative  factors,  including  local  nasal  factors
inﬂammation  and  infection),  medications,  and  systemic
actors  such  as  coagulation  disorders,  alcoholism,  hereditary
emorrhagic  telangiectasia,  and  hypertension.1,2
t
a
bThe  nose  has  a  rich  vascular  supply,  with  substantial  con-
ributions  from  the  internal  carotid  artery  (ICA)  and  the
xternal  carotid  artery  (ECA).  The  ECA  system  supplies  blood
o  the  nose  via  the  facial  and  internal  maxillary  arter-
es.  The  ICA  contributes  to  nasal  vascularity  through  the
phthalmic  artery.3 Kiesselbach’s  plexus  or  Little’s  area  is
n  anastomotic  network  of  vessels  located  in  the  anterior
artilaginous  septum.  Many  of  the  arteries  supplying  the
eptum  have  anastomotic  connections  at  this  site.  More
han  90%  of  bleedings  occur  in  the  anterior  region  and
rise  from  Little’s  area,  where  Kiesselbach’s  plexus  forms
n  the  septum.3 The  posterior  epistaxis,  which  is  usually
ore  profuse  and  arterial  in  origin,  occurs  further  back  inhe  nasal  cavity.  It  has  a greater  risk  of  airway  compromise,
spiration  of  blood,  and  greater  difﬁculty  in  controlling
leeding.
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found  in  the  demographic  features  and  laboratory  and
transthoracic  echocardiography  parameters  between  the
groups.
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Normotensive  epistaxis  
Hypertension  is  a  major  cause  of  spontaneous  epistaxis.
Patients  with  epistaxis  commonly  present  with  elevated
blood  pressure.  Epistaxis  is  more  common  in  hypertensive
patients,  perhaps  owing  to  vascular  fragility  from  the  long-
standing  disease.4 However,  epistaxis  patients  with  normal
blood  pressure  are  not  well  investigated  for  masked  hyper-
tension  (MH).
The  phenomenon  of  MH  is  deﬁned  as  a  clinical  condi-
tion  in  which  a  patient’s  ofﬁce  blood  pressure  (BP)  level  is
<140/90  mmHg,  but  the  ambulatory  or  home  BP  readings  are
in  the  hypertensive  range.4 The  high  prevalence  of  MH  sug-
gests  the  necessity  for  measuring  out-of-ofﬁce  BP  in  persons
with  apparently  normal  or  well-controlled  ofﬁce  BP.5 The
prevalence  of  MH  in  the  general  population  could  be  as  high
as  10%.  However,  data  obtained  from  several  cross-sectional
studies  have  demonstrated  large  differences,  with  preva-
lence  rates  ranging  from  a  low  of  8%  to  a  high  of  49%.6,7
Hypertension  by  24  h  ambulatory  blood  pressure  monitor-
ing  (ABPM)  is  deﬁned  when  the  mean  daytime  systolic  BP
is  equal  to  or  greater  than  135  mmHg  or  when  the  mean
daytime  diastolic  BP  is  equal  to  or  greater  than  85  mmHg,
according  to  the  seventh  report  of  the  2003  US  Hyper-
tension  Joint  National  Committee  and  European  Society  of
Hypertension.8
This  study  aimed  to  evaluate  the  prevalence  of  MH  using
ABPM  among  patients  with  epistaxis.
Methods
This  prospective  study  included  the  review  of  the  medical
charts  of  patients  with  mild,  moderate,  or  severe  epistaxis
that  was  treated  medically  or  surgically  between  Decem-
ber  2012  and  January  2015.  All  subjects  gave  their  informed
consent.  The  study  protocol  has  been  approved  by  the
ethics  committee  of  the  Kecioren  Hospital  (approval  No.
185-09.01.2013).
A  total  of  120  patients  participated  in  the  study.  Patients
were  separated  into  two  groups:  the  epistaxis  group  and
the  control  group  that  did  not  present  with  epistaxis.  Both
groups  included  60  patients,  and  each  group  had  40  male
and  20  female  patients.  Patients’  age  ranged  from  21  to
68  years  (mean  42.9)  for  the  epistaxis  group  and  18  to
71  years  (mean  42.2)  for  the  control  group.  The  inclu-
sion  criterion  was  spontaneous  epistaxis  (without  trauma
or  nasal  surgery)  with  normal  ofﬁce  BP  and  without  known
hypertension.  The  exclusion  criteria  included  chronic  liver
disease,  chronic  kidney  disease,  or  coagulopathy,  as  well
as  patients  who  were  taking  anti-thrombotic  drugs,  had
nasal  trauma,  had  undergone  nasal  surgery,  or  had  previous
hypertension.
After  patients’  BP  was  measured  and  active  nose  bleeding
was  stopped  by  medical  or  surgical  management,  laboratory
parameters  of  the  CBC,  INR,  and  APTT  tests  were  studied,
echocardiography  in  the  cardiology  clinic  was  conducted,
and  a  24  h  BPM  device  (Holter  device)  was  applied  to  each
patient.Normal  ofﬁce  BP  was  deﬁned  as  <140/90  mmHg.  MH  was
deﬁned  as  a  patient’s  ofﬁce  BP  level  of  <140/90  mmHg  and
ABPM  parameters  in  the  hypertensive  range  (24  h  average
BP  ≥  130/80  mmHg  and/or  daytime  average  ≥135/85  mmHg
and/or  night-time  average  ≥120/70  mmHg).
F
figure  1  Day  and  night  diastolic  blood  pressures  (BP)  were
igniﬁcantly  higher  for  the  epistaxis  group.
tatistical  analysis
ontinuous  parametric  and  nonparametric  data  are  pre-
ented  as  the  mean  ±  standard  deviation  (SD)  or  as  the
edian  (range),  respectively.  Non-continuous  variables  are
resented  as  percentages.  Categorical  variables  were  com-
ared  with  Pearson’s  chi-squared  test.  Continuous  variables
ere  compared  with  Student’s  t-test  and  Mann--Whitney  U
ests.  SPSS  v.  15.0  was  used  for  statistical  analyses.
esults
 total  of  60  patients  with  epistaxis  and  60  control  sub-
ects  were  enrolled  in  the  study.  The  mean  age  was  similar
etween  the  epistaxis  group  and  the  controls:  21--68  years
mean  42.9)  for  the  epistaxis  group  and  18--71  years  (mean
2.2)  for  the  control  group.  No  signiﬁcant  difference  wasAll sist BP Day sist BP Night sist BP
igure  2  Night  systolic  blood  pressure  (BP)  difference  was
ound to  be  higher  between  the  control  and  epistaxis  groups.
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Table  1  Ofﬁce  blood  pressure,  24  h  ambulatory  blood  pressure,  and  their  comparison  for  the  control  and  epistaxis  groups.
Control  (n  =  60)  Epistaxis  (n  =  60)  p
Mean, range  Mean,  range
Ofﬁce  blood  pressure  (mmHg)
Systolic  120.3  (128--110)  120.1  (128--110)  0.817
Diastolic 74.2  (85--58)  74.0  (85--55)  0.840
Average ABPM  BP  (mmHg)
24 h
Systolic  121.1  (134--114)  125.6  (149--99.5)  0.012
Diastolic 67.2  (87--51)  75.7  (116--55)  0.00
Day
Systolic 126.1  (145--107) 127.2(149--91) 0.517
Diastolic  71.4  (90--55)  75.1  (95--54)  0.009
Night
Systolic 109.2  (120--99)  117.2  (139--88)  0.00
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KDiastolic 63.8  (75--48)  
Twenty  patients  (33.3%)  in  the  epistaxis  group  and  seven
atients  (11.7%)  in  the  control  group  (p  =  0.004)  had  MH.
igs.  1  and  2  show  the  systolic  and  diastolic  BP  levels  in
he  epistaxis  and  control  groups.  The  ofﬁce  BP  and  ABPM
arameters  are  presented  in  Table  1.
Daytime  diastolic  BP,  24  h  systolic  and  diastolic  BP,  and
ighttime  systolic  and  diastolic  BP  were  signiﬁcantly  higher
n  patients  with  epistaxis  than  in  those  in  the  control  group.
owever,  no  signiﬁcant  difference  was  found  in  the  daytime
ystolic  BP  between  the  control  group  and  the  patients  with
pistaxis  (p  =  0.517).
iscussion
o  the  best  of  the  authors’  knowledge,  this  study  is  the
rst  to  investigate  MH  prevalence  in  patients  with  epistaxis.
he  study  shows  increased  MH  prevalence  in  patients  with
pistaxis.
Epistaxis  and  hypertension  are  frequent  conditions  in  the
dult  population.  The  relationship  between  the  level  of  arte-
ial  pressure  and  the  incidence  of  epistaxis  in  patients  with
ypertension  is  an  issue  that  appears  frequently  in  clinical
ractice.
Despite  overt  hypertension  representing  the  major  cause
f  spontaneous  epistaxis,  no  study  has  yet  evaluated  the
elationship  between  MH  and  epistaxis.  Compared  with
ther  measures,  the  24  h  ABPM  is  more  valuable  for  pre-
icting  prognosis,  as  it  more  accurately  assesses  the  risk  of
ardiovascular  disease  than  measurements  of  BP  made  dur-
ng  clinic  or  ofﬁce  visits,  and  ABPM  is  also  closely  related  to
amage  of  the  target  organ.9
Only  a  limited  number  of  ABPM  studies  have  examined
atients  with  epistaxis.  The  probable  reason  is  that  if  a
atient  presents  with  normal  ofﬁce  BP,  hardly  any  oto-
aryngologist  would  perform  ABPM.10 Recent  studies  on  the
anagement  of  patients  with  epistaxis  and  hypertension
o  not  mention  the  prevalence  of  MH  in  epistaxis  patients,
nd  only  recommend  the  use  of  ABPM  or  home  monitoring
evices  for  a  more  accurate  diagnostic  of  MH.11
p
p
e
f68.2  (88--48)  0.003
For  the  purpose  of  this  study,  patients  with  epistaxis
ith  no  history  of  hypertension  were  deliberately  chosen.
his  study  found  a  high  prevalence  of  MH  in  patients  with
pistaxis.  MH  was  present  in  20  (33.3%)  patients  in  the  epis-
axis  group  and  in  seven  (11.7%)  patients  in  the  control
roup.  Page  et  al.  showed  that  serious  spontaneous  epis-
axis  could  also  be  the  presenting  sign  of  an  underlying
vert  hypertension  in  about  43%  of  patients  with  no  his-
ory  of  hypertension.12 This  ﬁnding  could  be  attributed  to
he  selection  of  patients,  as  Page  et  al.  included  patients
ith  serious  epistaxis  only.  Comparing  the  present  results
ith  those  in  the  available  literature,  it  can  be  hypothe-
ized  that  MH  is  more  prevalent  in  patients  with  epistaxis
han  in  those  without.  Based  on  these  results,  more  large-
cale  studies  that  include  subjects  from  the  whole  spectrum
f  patients  with  epistaxis  and  arterial  hypertension  are
eeded.
The  present  study  used  more  common  but  stricter  criteria
or  MH.  The  criteria  are  justiﬁed  for  use  in  patients  with  epis-
axis  because  of  the  high  prevalence  of  MH  in  these  patients.
oreover,  the  nighttime  systolic  BP  was  signiﬁcantly  higher
n  patients  with  epistaxis  than  in  those  without.  This  ﬁnding
ay  present  evidence  on  the  greater  importance  of  noctur-
al  hypertension  in  the  pathophysiology  of  the  development
f  MH  than  the  simple  presence  of  daytime  BP.  More  studies
re  needed  for  a  better  understanding  of  the  pathophysio-
ogy  of  MH  development.
The  mechanism  of  how  MH  could  lead  to  epistaxis
emains  unknown.  One  of  the  mechanisms  may  be  related  to
ndothelial  dysfunction.  A  study  revealed  that  the  presence
f  MH  is  one  of  the  independent  determinants  of  cardio-
ascular  disease.6 Only  a  limited  number  of  studies  have
een  conducted  on  how  epistaxis  inﬂuences  MH  or  noc-
urnal  hypertension.  Proper  blood  pressure  management  is
ecessary  for  the  prevention  of  persistent  epistaxis  from
iesselbach’s  area  in  the  clinical  setting  of  emergency  care
ractice.13 In  the  authors’  clinical  practice,  most  epistaxis
atients  were  admitted  to  the  hospital  at  night,  and  MH  was
ffective  in  showing  cardiovascular  organ  damage.  There-
ore,  ABPM  should  be  performed  in  these  patients.
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Conclusion
This  study  demonstrated  that  MH  prevalence  is  higher  in
patients  with  epistaxis.  It  is  suggested  that  all  patients  with
epistaxis  should  undergo  ABPM  to  detect  MH,  which  could
be  a  possible  cause  of  epistaxis.
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